Journal
CANCER TREATMENT REVIEWS
Volume 35, Issue 8, Pages 685-691Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.ctrv.2009.08.001
Keywords
Breast cancer; HER2; Irreversible tyrosine kinase inhibitors; Neratinib; Lapatinib; Trastuzumab
Categories
Funding
- Spanish Association Against Cancer (AECC)
- FISCAM [PI-2007/41]
Ask authors/readers for more resources
Aberrant activation of HER2 through overexpression has been shown to play an important role in some breast cancers. Therapies against this receptor including the monoclonal antibody, trastuzumab, or the small tyrosine kinase inhibitor, lapatinib have shown to improve the prognosis of such patients. Despite overexpressing HER2, some patients do not respond to these targeted treatments or progress after a short period of time. Irreversible tyrosine kinase inhibitors have been developed to bypass several pathways that could be involved in this resistance. In vitro, these agents have been shown to be more potent and to prolong target inhibition. Clinical development of these agents is ongoing and early results are promising. This review will describe the biologic rationale that justifies the development of these agents in breast cancer focusing on the current status and future directions. (C) 2009 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available